Debt-to-equity of Inozyme Pharma, Inc. from 31 Mar 2021 to 31 Mar 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Inozyme Pharma, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 31 Mar 2025.
  • Inozyme Pharma, Inc. Debt-to-equity for the quarter ending 31 Mar 2025 was 94%, a 136% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Inozyme Pharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 94% +54% +136% 31 Mar 2025
Q4 2024 69% +32% +86% 31 Dec 2024
Q3 2024 55% +24% +79% 30 Sep 2024
Q2 2024 44% +17% +64% 30 Jun 2024
Q1 2024 40% +22% +121% 31 Mar 2024
Q4 2023 37% +24% +174% 31 Dec 2023
Q3 2023 31% +18% +146% 30 Sep 2023
Q2 2023 27% +16% +140% 30 Jun 2023
Q1 2023 18% +7% +66% 31 Mar 2023
Q4 2022 14% +5% +54% 31 Dec 2022
Q3 2022 13% +5% +66% 30 Sep 2022
Q2 2022 11% +4% +62% 30 Jun 2022
Q1 2022 11% +2% +17% 31 Mar 2022
Q4 2021 9% 31 Dec 2021
Q3 2021 8% 30 Sep 2021
Q2 2021 7% 30 Jun 2021
Q1 2021 9% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.